Abstract 1163P
Background
The immune checkpoint inhibitors (ICIs) revolutionized cancer therapeutic landscape and substantially improved the survival of patients (pts) with advanced malignancies. Several predictive biomarkers are under evaluation, in order to identify patients who can benefit from ICI. Recently, elevated NLR, calculated from absolute neutrophil count and white cell count, were found to be independent predictors of reduced survival and increased risk of progression in melanoma patients receiving ICI. The purpose of this study is to retrospectively investigate relationship of NLR with inflammation-immune mediators.
Methods
Gene profiling analysis was performed from 78 basal PBMCs of metastatic melanoma pts treated in first line with anti-PD1 using NanoString IO360 panel. Patient’s characteristics are listed in table. To identify the best genes signature the Sparse Partial Least Squares Discriminant Analysis (sPLS-DA) was applied.
Results
Overall, 78 patients were included in the analysis. Pts with high NLR at baseline (ratio >5.57) had a poorer PFS (HR=7.27, 95% CI = 3.5-14.8; p < 0.0001) and OS (HR=3.98; 95% CI = 2.0-7.9) than the pts with low NLR. Brain metastases were present in a higher proportion of pts with high NLR compared to those with low NLR (p=0.01). In the trascriptomic analysis, NLR was associated with SH2D1A, CD3, ZAP70, CD45RA genes, while a high NLR with CCNA1, LDHA, IL18R1, CD39, PTEN, MYD88 and MMP9 genes (ROC curve, AUC=0.97, p<0001). The signatures are also associated to response. In addition, CD39 expression is higher in NLR high and is associate with increase of N2 neutrophils. NLR increase on treatment is also associated to worse outcome and a specific genetic signature. Table: 1163P
Patient characteristics | N = 78 |
Median age | 61 (range 27-91) |
Gender: female/male, n (%) | 41 (53)/37 (47) |
Melanoma AJCC VII Stage | |
Stage IV, n (%) | 74 (94) |
Stage IIIC | 4 (5) |
Stage IIIB | 1 (1) |
CNS metastases at baseline, n (%) | 18 (23) |
BRAF Status | |
Wilde type, n (%) | 59 (76) |
Mutation, n (%) | 16 (21) |
NA, n (%) | 3 (3) |
Response rate at 1st assessment | |
Complete response, n (%) | 9 (11) |
Partial response, n (%) | 16 (21) |
Stable disease, n (%) | 17 (22) |
Progression disease, n (%) | 36 (46) |
ORR, n (%) | 39 (50) |
DCR, n (%) | 25 (32) |
LDH | |
High | 26 (33) |
Normal | 34 (44) |
NA | 18 (23) |
Conclusions
NLR high is related with immunosuppressive, inflammatory and tumor related genes; in particular with N2 neutrophils associate to adenosine pathway activation. This could explain the prognostic role of NLR. Further investigations are needed to get additional information.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Paolo Antonio Ascierto.
Funding
Italian Ministry of Health (IT-MOH).
Disclosure
A. White, M. Bailey, S. Ong, S.E. Church, S. Warren, A. Cesano: Financial Interests, Personal, Stocks or ownership: NanoString. P.A. Ascierto: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health. All other authors have declared no conflicts of interest.
Resources from the same session
1198P - Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings
Presenter: Jonathan Strosberg
Session: Poster session 13
1199P - MAVERIC: Phase II randomized study of everolimus as maintenance therapy for metastatic neuroendocrine neoplasms (mNEN) with pulmonary or gastroenteropancreatic (GEP) origin. Results on behalf of the GOIRC
Presenter: Lorenzo Antonuzzo
Session: Poster session 13
1200P - A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial
Presenter: oOttavia Clemente
Session: Poster session 13
1201P - Evaluation of efficacy TEMCAP regiment as first-line or further line therapy in patients with advanced, unresectable, progressive GEP-NET. Real-world data
Presenter: Agnieszka Kolasinska-Cwikla
Session: Poster session 13
1202P - Final analysis of TENEC trial: A phase II trial of temozolomide (TMZ) as second-line treatment for advanced neuroendocrine carcinomas (NEC) in patients (pts) with a poor performance status (PS)
Presenter: Claudia von Arx
Session: Poster session 13